2011
DOI: 10.1167/iovs.10-5768
|View full text |Cite
|
Sign up to set email alerts
|

TNFα Is Required for Late BRB Breakdown in Diabetic Retinopathy, and Its Inhibition Prevents Leukostasis and Protects Vessels and Neurons from Apoptosis

Abstract: Although neither TNFα nor inflammation is necessary for early BRB breakdown in DR, TNFα is critical for later complications and would be a good therapeutic target for the prevention of the progressive BRB breakdown, retinal leukostasis, and apoptosis associated with DR.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
159
0
1

Year Published

2011
2011
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 193 publications
(165 citation statements)
references
References 55 publications
5
159
0
1
Order By: Relevance
“…Recently, Huang and coworkers demonstrated that retinal leukostasis was abrogated in diabetic mice with disruption of the TNF-α gene [42]. Although diabetes did not significantly increase, and even decreased TNF-α mRNA expression in retinas of wild-type mice, lack of its expression in the knockout animals greatly reduced vascular leakage after 3 and 6 months of diabetes and neurodegeneration after 3 months of diabetes.…”
Section: Evidence For Inflammation In Drmentioning
confidence: 99%
“…Recently, Huang and coworkers demonstrated that retinal leukostasis was abrogated in diabetic mice with disruption of the TNF-α gene [42]. Although diabetes did not significantly increase, and even decreased TNF-α mRNA expression in retinas of wild-type mice, lack of its expression in the knockout animals greatly reduced vascular leakage after 3 and 6 months of diabetes and neurodegeneration after 3 months of diabetes.…”
Section: Evidence For Inflammation In Drmentioning
confidence: 99%
“…Two mouse models of diabetes were used: streptozotocin (STZ) treatment and insulin2 gene point mutation, both of which were described in our previous reports [11].…”
Section: Clinical and Experimental Ophthalmologymentioning
confidence: 99%
“…These dose ranges were chosen based on the antibody's clinical applications. The measurements were performed at 3 or 6 months, which were the time frames used in our previous mouse knockout (KO) study [11]. The treatment cohorts were described below and illustrated in Figure 1.…”
Section: Anti-tnfα Treatment Cohortsmentioning
confidence: 99%
See 2 more Smart Citations